Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment.

Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if REGENERON PHARMACEUTICALS (NASDAQ:REGN) is suited for quality investing. Investors should of course do their own research, but we spotted REGENERON PHARMACEUTICALS showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.

Why NASDAQ:REGN may be interesting for quality investors.

• REGENERON PHARMACEUTICALS has achieved substantial revenue growth over the past 5 years, with a 15.7% increase. This signifies the company's ability to successfully capture market opportunities and generate sustained revenue growth.
• REGENERON PHARMACEUTICALS exhibits a strong ROIC excluding cash and goodwill, indicating efficient capital utilization and profitable operations. The 21.99% reflects the company's ability to generate returns on invested capital and underscores its commitment to delivering value to shareholders.
• With a Debt/Free Cash Flow Ratio of 0.9, REGENERON PHARMACEUTICALS exhibits solid financial health and responsible debt management practices. This ratio indicates the company's ability to generate ample free cash flow to meet its debt obligations and pursue growth opportunities.
• REGENERON PHARMACEUTICALS demonstrates consistent Profit Quality over the past 5 years, with a strong 76.98%. This indicates the company's ability to generate sustainable and reliable profits, showcasing its long-term profitability and financial stability.
• REGENERON PHARMACEUTICALS has experienced impressive EBIT growth over the past 5 years, with 19.15% increase. This reflects the company's effective operational performance and highlights its potential for long-term financial success.
• With EBIT 5-year growth outpacing its Revenue 5-year growth, REGENERON PHARMACEUTICALS showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

What is the full fundamental picture of NASDAQ:REGN telling us.

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

REGN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 608 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN has a correct valuation and a medium growth rate.

Our latest full fundamental report of REGN contains the most current fundamental analsysis.

Our Caviar Cruise screen will find you more ideas suited for quality investing.

Disclaimer

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.